Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 1
2014 2
2015 2
2018 2
2019 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Bone metastases in germ cell tumor patients.
Oechsle K, Bokemeyer C, Kollmannsberger C, Mayer F, Berger LA, Oing C, Honecker F. Oechsle K, et al. Among authors: berger la. J Cancer Res Clin Oncol. 2012 Jun;138(6):947-52. doi: 10.1007/s00432-012-1169-3. Epub 2012 Feb 21. J Cancer Res Clin Oncol. 2012. PMID: 22350540 Clinical Trial.
Identification of a High-Level MET Amplification in CTCs and cfTNA of an ALK-Positive NSCLC Patient Developing Evasive Resistance to Crizotinib.
Berger LA, Janning M, Velthaus JL, Ben-Batalla I, Schatz S, Falk M, Iglauer P, Simon R, Cao R, Forcato C, Manaresi N, Bramlett K, Buson G, Hanssen A, Tiemann M, Sauter G, Bokemeyer C, Riethdorf S, Reck M, Pantel K, Wikman H, Loges S. Berger LA, et al. J Thorac Oncol. 2018 Dec;13(12):e243-e246. doi: 10.1016/j.jtho.2018.08.2025. Epub 2018 Sep 8. J Thorac Oncol. 2018. PMID: 30205165 Free article. No abstract available.
Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors.
Janning M, Kobus F, Babayan A, Wikman H, Velthaus JL, Bergmann S, Schatz S, Falk M, Berger LA, Böttcher LM, Päsler S, Gorges TM, O'Flaherty L, Hille C, Joosse SA, Simon R, Tiemann M, Bokemeyer C, Reck M, Riethdorf S, Pantel K, Loges S. Janning M, et al. Among authors: berger la. Cancers (Basel). 2019 Jun 17;11(6):835. doi: 10.3390/cancers11060835. Cancers (Basel). 2019. PMID: 31212989 Free PMC article.
Frequency of Circulating Tumor Cells (CTC) in Patients with Brain Metastases: Implications as a Risk Assessment Marker in Oligo-Metastatic Disease.
Hanssen A, Riebensahm C, Mohme M, Joosse SA, Velthaus JL, Berger LA, Bernreuther C, Glatzel M, Loges S, Lamszus K, Westphal M, Riethdorf S, Pantel K, Wikman H. Hanssen A, et al. Among authors: berger la. Cancers (Basel). 2018 Dec 19;10(12):527. doi: 10.3390/cancers10120527. Cancers (Basel). 2018. PMID: 30572662 Free PMC article.
First salvage treatment in patients with advanced germ cell cancer after cisplatin-based chemotherapy: analysis of a registry of the German Testicular Cancer Study Group (GTCSG).
Berger LA, Bokemeyer C, Lorch A, Hentrich M, Kopp HG, Gauler TC, Beyer J, de Wit M, Mayer F, Boehlke I, Oing C, Honecker F, Oechsle K. Berger LA, et al. J Cancer Res Clin Oncol. 2014 Jul;140(7):1211-20. doi: 10.1007/s00432-014-1661-z. Epub 2014 Apr 3. J Cancer Res Clin Oncol. 2014. PMID: 24696231
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.
Soria JC, Felip E, Cobo M, Lu S, Syrigos K, Lee KH, Göker E, Georgoulias V, Li W, Isla D, Guclu SZ, Morabito A, Min YJ, Ardizzoni A, Gadgeel SM, Wang B, Chand VK, Goss GD; LUX-Lung 8 Investigators. Soria JC, et al. Lancet Oncol. 2015 Aug;16(8):897-907. doi: 10.1016/S1470-2045(15)00006-6. Epub 2015 Jul 5. Lancet Oncol. 2015. PMID: 26156651 Clinical Trial.